Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD4 ChIP-seq and CUT&RUN on DU145 cells treated with CDK2 inhibitor Tegtociclib (PF-07104091) or with cyclin E1 overexpression

ABSTRACT: In this experiment, we performed BRD4 ChIP-seq on DU145 cells upon CDK2 inhibition by Tegtociclib (also known as PF-07104091, a CDK2 inhibitor developed by Pfizer). We also performed BRD4 CUT&RUN on cyclin E1-overexpressing DU145 cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE241291 | GEO | 2026/09/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Differentially expressed genes upon CDK2 inhibition by Tegtociclib (PF-07104091) in 3 HR+ BRCA cell lines

Project description:In this experiment, we use RNA-seq to examine the differentially expressed genes upon CDK2 inhibition by Tegtociclib (PF-07104091) in MCF7, T47D and HCC1428 cell lines

2026-09-28 | GSE318180 | GEO

Differentially expressed genes upon overexpression of cyclin E1, or cycin E1 together with CDK2 (E1CDK2)

Project description:In this experiment, we use RNA-seq to examine the differentially expressed genes upon overexpression of cyclin E1, or cyclin E1 together with CDK2, in different cell lines

2026-09-28 | GSE318181 | GEO

Differentially expressed genes in cells with CDK2 inhibition or genetic ablation, together with JQ1 treatment

Project description:In this experiment, we use RNA-seq to examine the differentially expressed genes in CDK2 knockout cells, or cells treated with 500 nM of CDK2 inhibitor PF-07104091 (tagtociclib), with or without co-treatment of 250 nM of BET inhibitor JQ1, for 3 days.

2026-09-28 | GSE290240 | GEO

The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles.

Project description: Not available

| S-EPMC548659 | biostudies-literature

Break CDK2/Cyclin E1 interface allosterically with small peptides.

Project description: Not available

| S-EPMC4188581 | biostudies-literature

Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma

Project description:CIC-rearranged sarcoma is an aggressive mesenchymal neoplasm characterized by capicua (CIC) gene rearrangement and molecular dependence on the CDK2-cyclin E complex. Given its high metastatic potential and poor clinical outcomes, there is an urgent need to identify biologic vulnerabilities for therapeutic targeting. Here, we determined the efficacy of CDK2-targeted therapies in preclinical models of CIC- rearranged sarcoma including two new cell lines and xenografts driven by CIC::DUX4 and CIC::NUTM1 fusion, respectively. Functional analyses revealed that CIC- rearranged sarcomas are MYC-driven cancers and can be targeted with the selective CDK2 inhibitor tagtociclib (PF-07104091) in vitro and in vivo. Concomitant with RB1- mediated proliferative arrest, tagtociclib inhibited MYC oncogenic programs. Moreover, combination of tagtociclib with the CDK9 inhibitors KB-0742 or AZD4573 was synergistic and enhanced apoptotic cell death in vitro and in vivo. These results demonstrate anti-tumor effects of concurrent inhibition of CDK2 and CDK9 through MYC transcriptional repression and provide a strong rationale for clinical evaluation of CDK2 and CDK9-targeted combination therapies in patients with CIC-rearranged sarcoma.

2026-03-10 | GSE291596 | GEO

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer

Project description:Intrinsic and acquired resistance to CDK4/6 inhibitors (CDK4/6i) is a critical challenge in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). CDK2 inhibitors (CDK2i) show promise in this context, with several currently under early-phase clinical evaluation. Here, by analyzing tumor and liquid biopsies from patients treated with the selective CDK2i PF-07104091, we observed that PF-07104091 monotherapy achieved disease stabilization in a cohort of CDK4/6i-resistant HR+/HER2- MBC patients. Notably, responses were observed irrespective of RB expression and phosphorylation, whereas non-progressive disease appeared more frequently among patients whose tumors retained wild-type TP53. Studies in established and patient-derived cell lines further substantiated that the growth suppressive effects of CDK2i were independent of RB status in CDK4/6i-resistant models. CDK2i activity reduced DNA replication rate, increased DNA damage, and inhibited mitotic entry, with growth inhibition dependent on p53 expression. These findings indicate that CDK dependency shifts from CDK4/6 toward CDK2 as cells transition from CDK4/6i-sensitive to CDK4/6i-resistant state. The distinct mechanisms of CDK2i and CDK4/6i support enhanced synergistic activity in HR+/HER2- MBC with acquired resistance to CDK4/6i therapy.

2026-05-14 | GSE265952 | GEO

anti-Flag, anti-H3K4me3 and anti-H3K27ac Cut&Run on DU145 cells with endogenous BRD4 knockout and re-introduced of Flag-tagged WT- or AA-BRD4

Project description:In this experiment, we performed anti-Flag, anti-H3K4me3 and anti-H3K27ac Cut&Run on DU145 cells with endogenous BRD4 knockout and re-introduced of Flag-tagged WT- or AA-BRD4.

2026-09-28 | GSE276952 | GEO

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.

Project description: Not available

| S-EPMC11700143 | biostudies-literature

FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A.

Project description: Not available

| S-EPMC5743019 | biostudies-literature